Lucia Bio
Brisbane, Australia· Est.
Australian‑focused biotech creating next‑generation oral Syk inhibitors for autoimmune, neuroinflammatory and oncology markets.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $3M
AI Company Overview
Australian‑focused biotech creating next‑generation oral Syk inhibitors for autoimmune, neuroinflammatory and oncology markets.
ImmunologyNeurologyOncology
Technology Platform
Highly selective oral small‑molecule Syk inhibitors designed via structure‑guided medicinal chemistry to achieve sub‑nanomolar potency and optimized CNS penetration.
Opportunities
First‑in‑human data could attract larger pharma partnerships and enable expansion into multiple autoimmune and neuroinflammatory indications.
Risk Factors
Preclinical stage carries high attrition risk; competition from existing Syk inhibitors may challenge market differentiation.
Competitive Landscape
Competes with fostamatinib, cerdulatinib, and other kinase inhibitors, but differentiates through superior selectivity, oral dosing, and CNS penetration.